Atacicept 150 mg

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

IgA Nephropathy (IgAN)

Conditions

IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease

Trial Timeline

Dec 1, 2024 → May 31, 2028

NCT ID

NCT06674577

About Atacicept 150 mg

Atacicept 150 mg is a phase 2 stage product being developed by Vera Therapeutics for IgA Nephropathy (IgAN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06674577. Target conditions include IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease.

What happened to similar drugs?

6 of 20 similar drugs in IgA Nephropathy (IgAN) were approved

Approved (6) Terminated (3) Active (11)

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mgAstraZenecaApproved

✅CyclosporineNovartisApproved

✅ForxigaNovo NordiskApproved

✅nisoldipine + lisinoprilBayerApproved

✅Intravenous Rituximab + ACE/ARBBiogenApproved

🔄olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06674577	Phase 2	Recruiting	Dec 1, 2024	May 31, 2028	IgA Nephropathy (IgAN)

Competing Products

20 competing products in IgA Nephropathy (IgAN)

See all competitors

Product	Company	Stage	Hype Score
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22
Tacrolimus + Placebo	Astellas Pharma	Phase 2	35
Rituximab + cyclosporine	Sun Pharmaceutical	Phase 3	32
Placebo + LY3016859	Eli Lilly	Phase 1/2	32
Dipeptidyl-Peptidase IV Inhibitors + Glucagon-Like Peptide 1	Eli Lilly	Pre-clinical	26
HR19042 Capsules + Placebo	Jiangsu Hengrui Medicine	Phase 2	35
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 capsule	Jiangsu Hengrui Medicine	Phase 1	29
Atrasentan + Placebo	AbbVie	Phase 3	32
Atrasentan	AbbVie	Phase 2	35
Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg	AstraZeneca	Approved	43
ALXN1920 + Placebo	AstraZeneca	Phase 2	42
Candesartan	AstraZeneca	Pre-clinical	26
Placebo + Atacicept 25 mg + Atacicept 75 mg	Merck	Phase 2	27
BION-1301 + Placebo	Novartis	Phase 3	44
MAU868 + Placebo	Novartis	Phase 2	27
Atrasentan	Novartis	Phase 2	39